Active ingredient description

Anifrolumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1) with high specificity and affinity. This binding inhibits type I IFN signalling thereby blocking the biologic activity of type I IFNs. Inhibition of type I IFN blocks plasma cell differentiation and normalises peripheral T-cell subsets, restoring the balance between adaptive and innate immunity that is dysregulated in SLE.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA51

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Summary of Product Characteristics (SPC)

External identifiers

CAS Substance: 1326232-46-5
DrugBank Drug: DB11976
RxNorm Ingredient: 2565276
UNII Identifier: 38RL9AE51Q


Anifrolumab is an active ingredient of these brands:

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Estonia (EE)

France (FR)

Ireland (IE)

Italy (IT)

Japan (JP)

Lithuania (LT)

Poland (PL)

Romania (RO)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.